Literature DB >> 2562844

Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure.

M Gheorghiade1, V Hall, J B Lakier, S Goldstein.   

Abstract

The effects of intravenous captopril and intravenous digoxin given separately and in combination on rest and exercise hemodynamics were studied in 16 patients with severe heart failure and sinus rhythm. When given separately, both captopril and digoxin decreased the pulmonary capillary wedge pressure by, respectively, 24% (p = 0.003) and 34% (p = 0.004) and systemic vascular resistance by 23% (p = 0.09) and 20% (p = 0.03). Only digoxin increased cardiac index by 23% (p = 0.03) and stroke work index by 52% (p = 0.01). During maximal exercise, captopril alone decreased systemic vascular resistance by 28% (p = 0.0002) and increased cardiac index by 33% (p = 0.02). Digoxin alone decreased pulmonary capillary wedge pressure by 11% (p = 0.04) and increased stroke work index by 44% (p = 0.01). The combination of captopril and digoxin resulted in a decrease in pulmonary capillary wedge pressure and systemic vascular resistance and an increase in cardiac index and stroke work index both at rest and during exercise that was greater than values observed with either drug given alone. Cardiac index response to the combination of captopril and digoxin correlated with baseline serum aldosterone concentration (r = 0.81, p less than 0.001) and plasma renin activity (r = 0.74, p less than 0.0002). A significant decrease in norepinephrine concentration was noted after digoxin was administered alone or added to captopril. These findings demonstrate that in patients with severe heart failure, the acute administration of captopril and digoxin has an independent salutary hemodynamic effect. The combination of these agents, however, has an adjunctive effect on cardiac function at rest and during exercise.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562844     DOI: 10.1016/0735-1097(89)90561-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

Review 1.  The vulnerable phase after hospitalization for heart failure.

Authors:  Stephen J Greene; Gregg C Fonarow; Muthiah Vaduganathan; Sadiya S Khan; Javed Butler; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 2.  When, and when not, to use digoxin in the elderly.

Authors:  A T Gosselink; D J van Veldhuisen; H J Crijns
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 3.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

4.  [Digitalis and theophylline: old and superfluous?].

Authors:  M Gosch; P Dovjak
Journal:  Z Gerontol Geriatr       Date:  2013-07       Impact factor: 1.281

Review 5.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

6.  Hemodynamic responses to small muscle mass exercise in heart failure patients with reduced ejection fraction.

Authors:  Zachary Barrett-O'Keefe; Joshua F Lee; Amanda Berbert; Melissa A H Witman; Jose Nativi-Nicolau; Josef Stehlik; Russell S Richardson; D Walter Wray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

Review 7.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

8.  Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Authors:  Andrew P Ambrosy; Ankeet S Bhatt; Amanda L Stebbins; Lisa M Wruck; Marat Fudim; Stephen J Greene; William E Kraus; Christopher M O'Connor; Ileana L Piña; David J Whellan; Robert J Mentz
Journal:  Am Heart J       Date:  2018-02-11       Impact factor: 4.749

Review 9.  Contemporary Controversies in Digoxin Use in Systolic Heart Failure.

Authors:  Chonyang L Albert; Forum Kamdar; Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 10.  Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.

Authors:  John R Teerlink; Marco Metra; Valerio Zacà; Hani N Sabbah; Gadi Cotter; Mihai Gheorghiade; Livio Dei Cas
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.